Paxlovid for nonhospitalized patients with <scp>COVID</scp>‐19-Reference-Cited by-同舟云学术

Paxlovid for nonhospitalized patients with COVID‐19

Published:2024-03-22 Issue:6 Volume:31 Page:621-623
ISSN:1069-6563
Container-title:Academic Emergency Medicine
language:en
Short-container-title:Academic Emergency Medicine

Author:

Johari Fatima¹^ORCID,Verma Rajesh²

Affiliation:

1. Department of Medicine, Division of Infectious Diseases Northwell Health Manhasset New York USA

2. Department of Emergency Medicine New York City Health + Hospitals/Kings County Brooklyn New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/acem.14896

Reference14 articles.

1. FDA News Release: Coronavirus (COVID‐19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID‐19. U.S. Food and Drug Administration.2021. Accessed January 9 2024.https://www.fda.gov/news‐events/press‐announcements/coronavirus‐covid‐19‐update‐fda‐authorizes‐first‐oral‐antiviral‐treatment‐covid‐19

2. FDA Grants full approval to Paxlovid, COVID‐19 antiviral treatment;Harris E;JAMA,2023

3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

4. Evaluation of Protease Inhibition for COVID‐19 in Standard‐Risk Patients (EPIC‐SR). ClinicalTrials.gov.2021. Accessed January 20 2024.https://classic.clinicaltrials.gov/ct2/show/results/NCT05011513?view=results

5. Platform adaptive trial of novel antivirals for early treatment of COVID‐19 In the community (PANORAMIC): protocol for a randomised controlled open‐label adaptive platform trial of community novel antiviral treatment of COVID‐19 in people at increased risk of more severe disease. doi:10.1136/bmjopen‐2022‐069176

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential consequences of ineffective COVID‐19 antiviral management;Academic Emergency Medicine;2024-05-20